Should everolimus be stopped after radiological progression in metastatic insulinoma? A “pro” point of view
- 4 January 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 71 (1), 256-257
- https://doi.org/10.1007/s12020-020-02570-4
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Should everolimus be stopped after radiological progression in metastatic insulinoma? A "cons" point of viewEndocrine, 2020
- Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRTActa Oncologica, 2020
- 177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumorsNuclear Medicine Communications, 2019
- Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine TumorsJournal of Clinical Endocrinology & Metabolism, 2019
- Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine TumorsClinical Cancer Research, 2017